MALCOLM BRENNER to Clinical Trials, Phase I as Topic
This is a "connection" page, showing publications MALCOLM BRENNER has written about Clinical Trials, Phase I as Topic.
Connection Strength
0.156
-
Add-back of allodepleted donor T cells to improve immune reconstitution after haplo-identical stem cell transplantation. Cytotherapy. 2005; 7(2):116-25.
Score: 0.060
-
Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma. Nat Commun. 2020 07 15; 11(1):3549.
Score: 0.044
-
Highlights of the second international conference on "Immunotherapy in Pediatric Oncology". Pediatr Hematol Oncol. 2011 Sep; 28(6):459-60.
Score: 0.024
-
Gene-marked autologous hematopoietic stem cell transplantation of autoimmune disease. J Clin Immunol. 2000 Jan; 20(1):1-9.
Score: 0.011
-
Retinoblastoma treatment. Science. 1999 Jul 30; 285(5428):663-4.
Score: 0.010
-
Stereotactic injection of herpes simplex thymidine kinase vector producer cells (PA317-G1Tk1SvNa.7) and intravenous ganciclovir for the treatment of progressive or recurrent primary supratentorial pediatric malignant brain tumors. Hum Gene Ther. 1995 Sep; 6(9):1231-55.
Score: 0.008